Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes

Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes
MISSISSAUGA, Ontario–(BUSINESS WIRE)– Sunovion Pharmaceuticals Inc. (Sunovion) announced today that Health Canada has approved KYNMOBI (apomorphine HCI) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). OFF episodes are the re- or worsening of PD symptoms otherwise controlled with oral levodopa/carbidopa. They may be characterized, in part, by tremor, stiffness, slowed movement or ... read more
Source: Parkinson CanadaPublished on 2020-06-17By Anne Marie Gabriel